Triple-Drug attack on liver cancer shows promise in early trial

NCT ID NCT06698250

Recruiting now Disease control Sponsor: Anwaar Saeed Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing whether a combination of three drugs—zanzalintinib, durvalumab, and tremelimumab—can shrink tumors in people with advanced liver cancer that cannot be removed surgically. The study will enroll 40 participants who have not received prior systemic therapy. Researchers aim to find the best dose and measure how many patients respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanzalintinib (XL-092) combined with durvalumab (Imfinzi) and tremelimumab (Imjudo)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Houston Methodist Neal Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Mays Cancer Center, UT Health San Antonio
NOT_YET_RECRUITING

San Antonio, Texas, 78229, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.